Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)

Historic Equity Income for Avalo Therapeutics (AVTX) over the last 2 years, with Q2 2020 value amounting to -$1.9 million.

  • Avalo Therapeutics' Equity Income changed N/A to -$1.9 million in Q2 2020 from the same period last year, while for Mar 2021 it was -$1.9 million, marking a year-over-year decrease of 12624.08%. This contributed to the annual value of $5.2 million for FY2020, which is 955660.46% up from last year.
  • Avalo Therapeutics' Equity Income amounted to -$1.9 million in Q2 2020.
  • Avalo Therapeutics' 5-year Equity Income high stood at $7.1 million for Q1 2020, and its period low was -$1.9 million during Q2 2020.